Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Analyst ratings and recent news for three high-yielding healthcare stocks are highlighted: Pfizer (PFE), Merck & Co. (MRK), and GSK plc (GSK). UBS maintained a Neutral rating on Pfizer, raising the price target to $25, while Guggenheim reiterated a Buy rating; Pfizer also submitted a New Drug Application to the FDA with Arvinas. Citigroup downgraded Merck from Buy to Neutral, cutting the price target to $84, while Guggenheim reiterated a Buy rating; Merck reported positive results from Phase 3 trials for hyperlipidemia treatment. Oppenheimer maintained an Outperform rating on GSK, raising the price target to $93, and Canaccord Genuity maintained a Buy rating, increasing the price target to $100; GSK's trial for urinary tract infections will stop early for efficacy.

Analysis

High-dividend yielding stocks in the healthcare sector are garnering attention in turbulent market conditions, with Pfizer, Merck & Co., and GSK plc presenting distinct profiles. Pfizer (PFE) offers a significant 7.37% dividend yield; UBS analyst Trung Huynh maintained a Neutral rating, raising the price target from $24 to $25 on April 30, 2025, while Guggenheim's Vamil Divan reiterated a Buy rating on March 18, 2025. A notable development for Pfizer is the New Drug Application submission to the FDA with its partner Arvinas. Merck & Co. (MRK), with a 4.10% dividend yield, faces mixed analyst sentiment: Citigroup's Andrew Baum downgraded the stock from Buy to Neutral, cutting the price target from $115 to $84 on May 14, 2025, whereas Guggenheim's Vamil Divan reiterated a Buy with a $115 price target on April 17, 2025. Merck recently reported positive topline results from its Phase 3 CORALreef trials for enlicitide decanoate. GSK plc (GSK) provides a 3.88% dividend yield and has received favorable analyst updates: Oppenheimer’s Rupesh Parikh maintained an Outperform rating, increasing the price target from $87 to $93 on February 13, 2025, and Canaccord Genuity’s Susan Anderson maintained a Buy, raising the target from $93 to $100 on February 7, 2025. GSK also announced its pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr will stop early for efficacy. The analysts mentioned have accuracy rates between 67% and 74%.

Key Decisions for Investors

• Investors should weigh Pfizer's leading 7.37% dividend yield against mixed analyst outlooks—UBS Neutral with a $25 price target (April 30, 2025) versus Guggenheim's Buy (March 18, 2025)—and closely monitor the FDA review process for its New Drug Application submitted with Arvinas.
• For Merck, the contrasting analyst actions—Citigroup's downgrade to Neutral with a price target cut to $84 (May 14, 2025) versus Guggenheim's maintained Buy at $115 (April 17, 2025)—necessitate a careful risk assessment, despite positive Phase 3 trial results for its hyperlipidemia drug.
• GSK's positive momentum, underscored by Outperform/Buy ratings from Oppenheimer (PT $93, Feb. 13, 2025) and Canaccord Genuity (PT $100, Feb. 7, 2025) and the early halt for efficacy of its Phase 3 cUTI trial, warrants consideration for portfolios seeking exposure to healthcare with strong catalysts and a 3.88% yield.
• Across these names, investors focused on high-yielding healthcare stocks should scrutinize individual company developments, divergent analyst perspectives, particularly the price target adjustments, and the cited analyst accuracy ratings (67-74%) when making allocation decisions.